AUSTIN, Texas, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Aspira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Aspira.
William Blair & Company, L.L.C. and Truist Securities, Inc. are acting as joint book-running managers for the offering, and Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-manager for the offering.
The offering is expected to close on February 8, 2021, subject to customary closing conditions.
Gross proceeds from the offering are expected to be approximately $45.0 million (or approximately $51.75 million if the underwriters exercise their option to purchase additional shares in full), before deducting underwriting discounts and offering expenses payable by Aspira. Aspira intends to use the net proceeds from the offering for sales and marketing, working capital and other general corporate purposes, including investing in additional key strategic hires, product portfolio expansion and research and development. Aspira may also use a portion of the net proceeds from the offering to acquire or invest in complimentary businesses, technologies, product candidates or other intellectual property, although Aspira has no present commitments or agreements to do so.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment Aspira has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
